Homeβ€ΊStocksβ€ΊWOCKPHARMA: Wockhardt Ltd

Wockhardt Ltd

NSEBSEWOCKPHARMAHealthcareConcall transcript
β‚Ή1,996.40
β–Ό -β‚Ή33.20 Β (-1.64%)
NSE Β· Last Β· 11 Oct, 06:05 pm
Price
daily

Overlay is FY EPS implied P/E (stepped), not TTM.

Quant & risk snapshot

Metrics calculated as of last available close.

1W
β€”
1M
β€”
3M
β€”
6M
β€”
1Y
β€”
P/E now
β€”
3Y CAGR
β€”
5Y CAGR
β€”
1Y vol
β€”
5Y max DD
β€”
5Y EPS CAGR
β€”
5Y rerating
β€”
46
Empire Scoreβ„’
Fair
3
Piotroski
3/9 F-Score
6.1%
ROE
Return on equity
7.5%
ROCE
Return on capital
GRAHAM VALUE
β‚Ή428.07
~366% Premium
The Numbers That Matter
End-of-day filing snapshot Β· β€” when not disclosed
β€”EV / EBITDA
Financial Health Story
Revenue
Net Profit
Data is compiled from end-of-day institutional filings for educational structural analysis. Compare with audited filings before making financial decisions. Missing bars or β€” values are normal for banks or thin coverage. Chart magnitudes are shown in β‚Ή Cr (Indian grouping).
SWOT Analysis
AI Powered

Unlock strengths, weaknesses, opportunities, and threats in clear, simple English.

Peter Lynch valuation bands

Bands from median Β±1Οƒ of FY-implied P/E over the plotted window. These are not TTM percentile bands.

Base-100 compounding

Price, revenue, and net profit rebased to 100 at the first month where all series are positive. Annual fundamentals are step-held to month-end.

Peer Comparison

Sector: HealthcareΒ· 50 sector peers

Scroll horizontally to compare all sector peers.

MetricsWOCKPHARMAYouAPOLLOHOSPApollo Hospitals Enterprise LtdCIPLACipla LtdDIVISLABDivis Laboratories LtdDRREDDYDr Reddys Laboratories LtdSUNPHARMASun Pharmaceutical Industries LtdABBOTINDIAAbbott India LtdAJANTPHARMAjanta Pharma LtdALKEMAlkem Laboratories LtdANTHEMAnthem Biosciences LtdASTERDMAster DM Quality Care LtdAUROPHARMAAurobindo Pharma LtdBIOCONBiocon LtdBLUEJETBlue Jet Healthcare LtdCAPLIPOINTCaplin Point Laboratories LtdCOHANCECohance Lifesciences LtdCONCORDBIOConcord Biotech LtdEMCUREEmcure Pharmaceuticals LtdERISERIS Lifesciences LtdFORTISFortis Healthcare LtdGLANDGland Pharma LtdGLAXOGlaxosmithkline Pharmaceuticals LtdGLENMARKGlenmark Pharmaceuticals LtdGRANULESGranules India LtdIKSInventurus Knowledge Solutions LtdINDGNIndegene LtdIPCALABIpca Laboratories LtdJBCHEPHARMJ B Chemicals & Pharmaceuticals LtdJUBLPHARMAJubilant Pharmova LtdKIMSKrishna Institute of Medical Sciences LtdLALPATHLABDr Lal Pathlabs LtdLAURUSLABSLaurus Labs LtdLENSKARTLenskart Solutions LtdLUPINLupin LtdMANKINDMankind Pharma LtdMAXHEALTHMax Healthcare Institute LtdMEDANTAGlobal Health LtdNATCOPHARMNatco Pharma LtdNEULANDLABNeuland Laboratories LtdNHNarayana Hrudayalaya LtdONESOURCEOneSource Specialty Pharma LtdPFIZERPfizer LtdPOLYMEDPoly Medicure LtdPPLPHARMAPiramal Pharma LtdRAINBOWRainbow Childrens Medicare LtdSAGILITYSagility LtdSAILIFESai Life Sciences LtdSYNGENESyngene International LtdTORNTPHARMTorrent Pharmaceuticals LtdVIJAYAVijaya Diagnostic Centre LtdZYDUSLIFEZydus Lifesciences Ltd
Current Priceβ‚Ή1,996.4β‚Ή8,089.5β‚Ή1,379.3β‚Ή6,533β‚Ή1,274β‚Ή1,747.3β‚Ή26,295β‚Ή2,912.2β‚Ή5,239β‚Ή755.6β‚Ή726.95β‚Ή1,429.2β‚Ή416.8β‚Ή452.5β‚Ή1,988.1β‚Ή428.9β‚Ή1,166.2β‚Ή1,704.4β‚Ή1,362.1β‚Ή929.4β‚Ή2,277β‚Ή2,188.8β‚Ή2,184.6β‚Ή777.55β‚Ή1,670.2β‚Ή518.45β‚Ή1,507.7β‚Ή2,129.6β‚Ή991.75β‚Ή784.45β‚Ή1,617.2β‚Ή1,381.7β‚Ή521β‚Ή2,249.8β‚Ή2,420.4β‚Ή993.45β‚Ή1,105.55β‚Ή1,092β‚Ή14,449β‚Ή1,770.5β‚Ή1,784.8β‚Ή4,764β‚Ή1,321.4β‚Ή166.29β‚Ή1,241.9β‚Ή41.74β‚Ή1,047.95β‚Ή440.25β‚Ή4,182.9β‚Ή1,513.6β‚Ή1,203.9
P/E Ratio92.3Γ—59.8Γ—30.7Γ—82.9Γ—30.0Γ—35.3Γ—0.0Γ—38.8Γ—27.4Γ—87.4Γ—183.0Γ—25.4Γ—84.4Γ—77.1Γ—29.9Γ—156.0Γ—55.1Γ—34.9Γ—27.5Γ—62.8Γ—41.6Γ—45.7Γ—21.7Γ—32.7Γ—39.1Γ—33.5Γ—36.1Γ—53.8Γ—41.8Γ—155.0Γ—57.5Γ—96.3Γ—182.0Γ—16.0Γ—44.4Γ—67.2Γ—66.9Γ—12.8Γ—58.8Γ—44.5Γ—0.0Γ—120.0Γ—54.9Γ—0.0Γ—52.6Γ—20.5Γ—89.5Γ—51.7Γ—82.2Γ—83.2Γ—24.7Γ—
P/B Ratio7.4Γ—13.1Γ—3.3Γ—10.3Γ—2.6Γ—5.3Γ—0.0Γ—9.5Γ—4.6Γ—16.0Γ—14.4Γ—2.4Γ—2.0Γ—0.0Γ—5.1Γ—4.5Γ—8.0Γ—6.8Γ—4.6Γ—6.8Γ—4.4Γ—19.4Γ—5.9Γ—4.3Γ—10.6Γ—4.3Γ—5.7Γ—8.2Γ—1.9Γ—8.9Γ—12.1Γ—17.4Γ—12.2Γ—4.3Γ—5.9Γ—9.0Γ—9.4Γ—1.7Γ—14.8Γ—7.8Γ—3.0Γ—0.0Γ—5.7Γ—3.5Γ—8.7Γ—2.0Γ—12.0Γ—3.4Γ—15.6Γ—16.3Γ—4.5Γ—
ROE (%)6.1%21.2%11.6%16.5%11.2%16.0%34.7%27.1%18.9%22.3%11.3%10.1%1.4%52.1%20.9%4.9%12.5%20.1%18.7%11.2%10.7%45.6%23.6%13.8%31.4%14.4%15.7%18.9%6.5%11.3%22.3%18.3%6.3%28.7%13.1%14.7%15.2%17.1%21.2%20.5%-1.1%19.8%9.0%-3.8%15.9%10.6%15.4%7.8%27.4%18.3%21.2%
ROCE (%)7.5%17.4%15.5%22.0%13.0%20.5%46.7%34.5%21.2%30.4%11.6%12.9%3.6%57.3%24.2%5.8%17.1%24.0%14.1%13.4%15.1%61.4%39.8%15.5%31.5%18.8%17.0%25.4%9.0%9.5%28.0%17.8%8.1%29.9%13.5%14.7%17.4%17.4%26.5%15.5%57.0%27.2%12.5%2.5%17.4%13.4%19.6%10.0%15.2%20.5%21.1%
EV / EBITDAβ€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”
Dividend Yield (%)0.00%23.00%95.00%33.00%70.00%86.00%1.96%91.00%1.01%22.00%40.00%24.00%13.00%21.00%31.00%0.00%52.00%19.00%55.00%11.00%70.00%2.02%21.00%21.00%0.00%39.00%31.00%91.00%50.00%0.00%73.00%10.00%0.00%88.00%4.00%20.00%4.00%61.00%15.00%24.00%0.00%1.86%21.00%7.00%24.00%33.00%0.00%33.00%79.00%13.00%8.00%

Peer figures are drawn from the same educational filing snapshot as the main report. Missing values show β€”. EV/EBITDA and yields are often unavailable for banks. Compare filings before investing.

Corporate filings

Annual reports, investor decks, and concall links. URLs only. We do not host PDFs.

Annual reports

Newest period first.

Annual Report 2026
Annual Report 2026
Open
Financial Year 2026 from bse
Financial Year 2026 from bseLatest
Open
Annual Report 2025
Annual Report 2025
Open
Financial Year 2025 from bse
Financial Year 2025 from bse
Open
Annual Report 2024
Annual Report 2024
Open
Financial Year 2024 from bse
Financial Year 2024 from bse
Open
Annual Report 2023
Annual Report 2023
Open
Financial Year 2023 from bse
Financial Year 2023 from bse
Open
Annual Report 2022
Annual Report 2022
Open
Financial Year 2022 from bse
Financial Year 2022 from bse
Open
Annual Report 2021
Annual Report 2021
Open
Annual Report 2020
Annual Report 2020
Open
Annual Report 2019
Annual Report 2019
Open
Annual Report 2018
Annual Report 2018
Open
Annual Report 2017
Annual Report 2017
Open
Annual Report 2016
Annual Report 2016
Open
Annual Report 2015
Annual Report 2015
Open

Investor presentations

Newest period first.

Investor presentation β€” Jun 2026
Jun 2026Latest
Open
Investor presentation β€” Jun 2025
Jun 2025
Open
Investor presentation β€” Feb 2025
Feb 2025
Open
Investor presentation β€” Oct 2024
Oct 2024
Open

Concall transcripts

Newest period first.

Concall transcript β€” Jun 2026
Jun 2026Latest
Open
Concall transcript β€” Jun 2025
Jun 2025
Open
Concall transcript β€” Feb 2023
Feb 2023
Open
Technical Snapshot
Educational only
Technical data shown for educational purposes. Not investment advice.
Financial Health Checklist
2/9 passΒ· 1 data N/A
WATCH
Quarterly revenue growth2 of 3 period-over-period moves are up; trend is mixed.
PASS
Net profit trendAll last 4 quarters are profitable.
FAIL
ROEROE 6.1% (<10%).
FAIL
ROCEROCE 7.5% (<8%).
FAIL
Debt / EquityD/E 42.28 (β‰₯2.0).
PASS
Net marginNet margin 11.2% (β‰₯10%).
FAIL
P/E ratioP/E 92.3Γ— (β‰₯60).
N/A
EV / EBITDAData unavailable for this sector.
FAIL
Dividend yieldNo meaningful dividend yield reported.

N/A means the metric is not available in the educational dataset (common for banks or thin coverage). Those rows are not scored as fail.

Institutional ratios

Piotroski F-Score, Altman Z, cash conversion cycle, and PEG. Derived from the same filing-based fundamentals as the rest of the report (indicative only, not investment advice).

Piotroski F-Score
3/9
Altman Z-Score
2.71Grey
Cash conversion cycle
β€”
PEG ratio
341.84
Latest News
Tap a headline Β· Quick read
Loading headlines…